BRINSUPRI
Aug 25, 2025
Insmed’s BRINSUPRI, the First DPP1 Inhibitor: A New Era in NCFB Treatment
Insmed’s BRINSUPRI (brensocatib) has achieved a significant regulatory milestone, becoming the first FDA-approved therapy for non-cystic fibrosis bronchiectasis (NCFB) as well as the first approved DPP1 inhibitor. As the only NCFB treatment, this marks not just a scientific breakthrough but also a transformation in...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
